Novo Nordisk to acquire Forma Therapeutics in USD 1.1bn deal

Expanding its presence within sickle cell disease, the Danish pharmaceutical firm revealed on Thursday that it will acquire the US-based company for USD 20 per share. (Updated)

Photo: Stine Tidsvilde

Novo Nordisk has inked a definitive deal with Forma Therapeutics, whereby the Danish firm will pay USD 20 for all outstanding shares in the US-based biotech firm, amounting to a total price of USD 1.1bn, a press release announced on Thursday.

Forma Therapeutics specializes in sickle cell disease and rare blood disorders, and the company’s lead candidate, etavopivat, is being developed as a once-daily treatment for the chronic disease that affects red blood cells’ ability to effectively deliver oxygen. The drug has undergone phase I clinical testing, where it displayed a ”safe and well-tolerated” profile.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs